miR-297 modulates multidrug resistance in human colorectal carcinoma by down-regulating MRP-2
The DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.
Abstract
Colorectal carcinoma is a frequent cause of cancer-related death in men and women. miRNAs (microRNAs) are endogenous small non-coding RNAs that regulate gene expression negatively at the post-transcriptional level. In the present study we investigated the possible role of microRNAs in the development of MDR (multidrug resistance) in colorectal carcinoma cells. We analysed miRNA expression levels between MDR colorectal carcinoma cell line HCT116/L-OHP cells and their parent cell line HCT116 using a miRNA microarray. miR-297 showed lower expression in HCT116/L-OHP cells compared with its parental cells. MRP-2 (MDR-associated protein 2) is an important MDR protein in platinum-drug-resistance cells and is a predicted target of miR-297. Additionally miR-297 was down-regulated in a panel of human colorectal carcinoma tissues and negatively correlated with expression levels of MRP-2. Furthermore, we found that ectopic expression of miR-297 in MDR colorectal carcinoma cells reduced MRP-2 protein level and sensitized these cells to anti-cancer drugs in vitro and in vivo. Taken together, our findings suggest that miR-297 could play a role in the development of MDR in colorectal carcinoma cells, at least in part by modulation of MRP-2.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, several studies have demonstrated that using miRNA mimics to increase the levels of specific miRNAs, such as miR-133b, miR-142-3p, miR-297, and miR-522, can increase the chemosensitivity of drug-resistant CRC cells [104,105,106,107].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [104]
Citations
Cites
1 retracted
Liang, Z., Wu, H., Reddy, S., Zhu, A., Wang, S., Blevins, D. P., Yoon, Y., Zhang, Y., & Shim, H. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.09.007 · Cited by 126
RetractedJemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Bartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
Lewis, B. P., Burge, C. B., & Bartel, D. P. (2005) · Cell · doi:10.1016/j.cell.2004.12.035 · Cited by 11,855
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Real-time quantification of microRNAs by stem-loop RT-PCR
Chen, C. (2005) · Nucleic Acids Research · doi:10.1093/nar/gni178 · Cited by 4,952
Targeting multidrug resistance in cancer
Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1984 · Cited by 3,609
miR-15 and miR-16 induce apoptosis by targeting BCL2
Cimmino, A., Calin, G. A., Fabbri, M., Iorio, M. V., Ferracin, M., Shimizu, M., Wojcik, S. E., Aqeilan, R. I., Zupo, S., Dono, M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506654102 · Cited by 3,517
microRNAs as oncogenes and tumor suppressors
Zhang, B., Pan, X., Cobb, G. P., & Anderson, T. A. (2007) · Developmental Biology · doi:10.1016/j.ydbio.2006.08.028 · Cited by 2,749
Tumour invasion and metastasis initiated by microRNA-10b in breast cancer
Ma, L., Teruya-Feldstein, J., & Weinberg, R. A. (2007) · Nature · doi:10.1038/nature06174 · Cited by 2,605
Research works printed but not linked: 2
- Tokunaga, 2001, Effects of after surgery, Oncol. Rep., 8, 815
- Pan, 2009, MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells, Mol. Pharmacol., 75, 1374, 10.1124/mol.108.054163 · DOI · Paper page
Cited by
The sinister face of heme oxygenase-1 in brain aging and disease
Schipper, H. M., Song, W., Tavitian, A., & Cressatti, M. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.06.008 · Cited by 200
Multidrug Resistance Proteins (MRPs) and Cancer Therapy
Zhang, Y.-K., Wang, Y.-J., Gupta, P., & Chen, Z.-S. (2015) · The AAPS Journal · doi:10.1208/s12248-015-9757-1 · Cited by 196
MicroRNAs and cancer stem cells: the sword and the shield
Sun, X., Jiao, X., Pestell, T. G., Fan, C., Qin, S., Mirabelli, E., Ren, H., & Pestell, R. G. (2014) · Oncogene · doi:10.1038/onc.2013.492 · Cited by 161
Dai, X., & Tan, C. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.09.010 · Cited by 155
MicroRNAs: Clinical Relevance in Colorectal Cancer
Thomas, J., Ohtsuka, M., Pichler, M., & Ling, H. Y. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161226080 · Cited by 131
Tokarz, P., & Błasiak, J. (2012) · Acta Biochimica Polonica · doi:10.18388/abp.2012_2079 · Cited by 123
MicroRNAs as novel biomarkers for colorectal cancer: New outlooks
Shirafkan, N., Mansoori, B., Mohammadi, A., Shomali, N., Ghasbi, M., & Baradaran, B. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.11.046 · Cited by 124
Liao, H., Bai, Y., Qiu, S., Zheng, L., Huang, L., Liu, T., Wang, X., Liu, Y., Xu, N., Yan, X., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3563 · Cited by 109
“However, not many reports [18-21] explored the involvement of miRNAs in the development of multidrug resistance in cancer.”
Cancerous ovarian stem cells: Obscure targets for therapy but relevant to chemoresistance
Ahmed, N., Abubaker, K., Findlay, J. K., & Quinn, M. A. (2012) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24317 · Cited by 115
“This study is further supported by the commercial availability of miRNA mimics (Sigma–Aldrich, Life Technology) which can regulate the expression of specified miRNAs in vitro studies [Thorsen et al., 2012; Xu et al., 2012ab].”
ResultXie, H., Wu, Q., Zhu, B., Chen, F., Ji, L., Li, S., Wang, C., Tong, Y., Tuo, L., Wu, M., et al. (2014) · Tumor Biology · doi:10.1007/s13277-014-2013-y · Cited by 107
Micro RNA s and their relevance to ABC transporters
Haenisch, S., Werk, A. N., & Cascorbi, I. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12251 · Cited by 108
Serum miR-19a Predicts Resistance to FOLFOX Chemotherapy in Advanced Colorectal Cancer Cases
Chen, Q., Xia, H., Ge, X.-J., Zhang, Y., Tang, Q., & Bi, F. (2013) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2013.14.12.7421 · Cited by 103
“, 2012) or oxaliplatin (Akao et al., 2011; Chai et al., 2011; Xu et al., 2012; Xu et al., 2013).”
BackgroundCeballos, M. P., Rigalli, J. P., Ceré, L. I., Semeniuk, M., Catania, V. A., & Ruiz, M. L. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180105103637 · Cited by 101
Differentially Expressed Wound Healing-Related microRNAs in the Human Diabetic Cornea
Funari, V. A., Winkler, M., Brown, J. S., Dimitrijevich, S. D., Ljubimov, A. V., & Saghizadeh, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0084425 · Cited by 89
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“Moreover, several studies have demonstrated that using miRNA mimics to increase the levels of specific miRNAs, such as miR-133b, miR-142-3p, miR-297, and miR-522, can increase the chemosensitivity of drug-resistant CRC cells [104–107].”
Yu, A., Tian, Y., Tu, M., Ho, P. Y., & Jilek, J. L. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.067470 · Cited by 81
“…assay, mRNA and protein expression, and functional assay Zhan et al., 2013 miR-297 Reporter assay, mRNA and protein expression, and functional assay Xu et al., 2012a miR-379 Reporter assay, mRNA and protein expression, and functional assays Haenisch et al., 2011; Werk et al., 2014 ABCC4/MRP4…”
BackgroundMethodFang, Z., Xu, C., Li, Y., Cai, X., Ren, S., Liu, H., Wang, Y., Wang, F., Chen, R., Qu, M., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.01.033 · Cited by 80
To, K. K. W. (2013) · Journal of Biomedical Science · doi:10.1186/1423-0127-20-99 · Cited by 84
“ABCC2 miR-297↓ Luciferase reporter/miRNA mimic/miRNA inhibitor TargetScan miRNA microarray profiling Colorectal Yes [31]”
BackgroundMicroRNA‐106a induces multidrug resistance in gastric cancer by targeting RUNX3
Zhang, Y., Lu, Q., & Cai, X. (2013) · FEBS Letters · doi:10.1016/j.febslet.2013.06.058 · Cited by 77
“Recently, microRNAs (miRNAs) have been proposed to play essential roles in the development of MDR [5].”
BackgroundNon-Coding RNAs and Resistance to Anticancer Drugs in Gastrointestinal Tumors
Hahne, J. C., & Valeri, N. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00226 · Cited by 75
“Interestingly, in vitro and in vivo models suggest that resistance to vincristine and oxaliplatin could be overcome by restoring miR-297 expression in therapy-resistant cells (166).”
BackgroundInfluentialRole of miR-27a, miR-181a and miR-20b in gastric cancer hypoxia-induced chemoresistance
Danza, K., Silvestris, N., Simone, G., Signorile, M., Saragoni, L., Brunetti, O., Monti, M., Mazzotta, A., Summa, S. D., Mangia, A., et al. (2016) · Cancer Biology & Therapy · doi:10.1080/15384047.2016.1139244 · Cited by 73
“Recently, miRNAs have been suggested to play a key role in the development of MDR.(24)”
BackgroundMicroRNAs are important regulators of drug resistance in colorectal cancer
Zhang, Y., & Wang, J. (2017) · Biological Chemistry · doi:10.1515/hsz-2016-0308 · Cited by 69
“For example, miR-297 sensitizes CRC to multiple therapeutic agents in vitro and in vivo by down-regulating expression of MRP-2, which is an important MDR protein in platinum drug-resistant cells (Ke et al., 2012).”
BackgroundMicroRNAs in colorectal cancer: Role in metastasis and clinical perspectives
Muhammad, S., Kaur, K., Huang, R., Zhang, Q., Kaur, P., Yazdani, H. O., Bilal, M. U., Zheng, J., Zheng, L., & Wang, X.-S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i45.17011 · Cited by 65
Involvement of Non-coding RNAs in Chemo- and Radioresistance of Colorectal Cancer
Fanale, D., Castiglia, M., Bazan, V., & Russo, A. D. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-42059-2_11 · Cited by 62
“[ 110 ] showed that miR297 down-regulation was involved in a MDR mechanism conferring L-OHP resistance mediated by up-regulation of the ABCC2 gene encoding the MDR-associated protein 2 (MPR-2).”
BackgroundMethodInfluentialATP-binding cassette transmembrane transporters and their epigenetic control in cancer: an overview
Arrigoni, E., Galimberti, S., Petrini, M., Danesi, R., & Paolo, A. D. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2016.1215423 · Cited by 64
Zhang, C.-Z. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.05.155 · Cited by 59
Ikemura, K., Iwamoto, T., & Okuda, M. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.03.002 · Cited by 64
MicroRNAs and colorectal cancer chemoresistance: New solution for old problem
Vaghari-Tabari, M., Majidinia, M., Moein, S., Qujeq, D., Asemi, Z., Alemi, F., Mohamadzadeh, R., Targhazeh, N., Safa, A., & Yousefi, B. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118255 · Cited by 58
Elevated expression of tumor miR-222 in pancreatic cancer is associated with Ki67 and poor prognosis
Lee, C.-L., He, H., Jiang, Y., Yang, D., Yang, F., Li, J., Jin, C., & Fu, D. (2013) · Medical Oncology · doi:10.1007/s12032-013-0700-y · Cited by 58
miR-503-5p confers drug resistance by targeting PUMA in colorectal carcinoma
Xu, K., Chen, G., Qiu, Y., Yuan, Z., Li, H., Yuan, X., Sun, J., Xu, J., Liang, X., & Yin, P. (2017) · Oncotarget · doi:10.18632/oncotarget.15559 · Cited by 60
“injection every 4 days for 4 weeks [23].”
Self-citationColorectal Cancer: From the Genetic Model to Posttranscriptional Regulation by Noncoding RNAs
Lizarbe, M. A., Calle-Espinosa, J., Fernández-Lizarbe, E., Fernández‐Lizarbe, S., Robles-Ramos, M. Á., Olmo, N., & Turnay, J. (2017) · BioMed Research International · doi:10.1155/2017/7354260 · Cited by 57
Nanocarrier-Based Co-Delivery of Small Molecules and siRNA/miRNA for Treatment of Cancer
Chitkara, D., Singh, S. P., & Mittal, A. (2016) · Therapeutic Delivery · doi:10.4155/tde-2015-0003 · Cited by 53
MicroRNAs in colorectal cancer as markers and targets: Recent advances
Ye, J., & Cao, J. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i15.4288 · Cited by 57
Lin, S., Lei, K., Du, W., Yang, L., Shi, H., Gao, Y., Yin, P., Liang, X., & Liu, J. (2015) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2015.12.003 · Cited by 48
Self-citationTo, K. K. W., Huang, Z., Zhang, H., Ashby, C. R., & Fu, L. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101058 · Cited by 51
MicroRNAs and Cancer Drug Resistance
Gomes, B. C., Rueff, J., & Rodrigues, A. S. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3347-1_9 · Cited by 46
MicroRNAs associated with inflammation in shoulder tendinopathy and glenohumeral arthritis
Thankam, F. G., Boosani, C. S., Dilisio, M. F., & Agrawal, D. K. (2017) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-017-3097-7 · Cited by 47
“hsa-miR-297, another potentially upregulated miRNA in Group 1 tendons, is involved in multidrug resistance (MDR) in cancer cells by modulating MRP-2 (MDR-associated protein-2) [56].”
BackgroundmicroRNAs in cancer chemoresistance: The sword and the shield
Mondal, P., & Meeran, S. M. (2021) · Non-coding RNA Research · doi:10.1016/j.ncrna.2021.12.001 · Cited by 40
Marjaneh, R. M., Khazaei, M., Ferns, G. A., Avan, A., & Aghaee‐Bakhtiari, S. H. (2019) · IUBMB Life · doi:10.1002/iub.2108 · Cited by 38
“miR-297 Oxaliplatin - vincristine # • Downregulation of ABCC2 Xu et al.(59) 1436 MORADI MARJANEH ET AL.”
BackgroundThe Role of miRNAs in Dexmedetomidine’s Neuroprotective Effects against Brain Disorders
Burlacu, C.-C., Neag, M. A., Mitre, A. O., Sîrbu, A. C., Bădulescu, A.-V., & Buzoianu, A. D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105452 · Cited by 39
miR‐297 acts as an oncogene by targeting GPC 5 in lung adenocarcinoma
Sun, Y., Zhao, J., Yin, X., Yuan, X., Guo, J., & Bi, J. (2016) · Cell Proliferation · doi:10.1111/cpr.12288 · Cited by 37
MiRNAs and miRNA Polymorphisms Modify Drug Response
Li, M.-P., Hu, Y., Hu, X., Zhang, Y., Yang, Y., Jiang, C. L., Tang, J., & Chen, X.-P. (2016) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph13111096 · Cited by 36
“MiR-297 was proved to reduce ABCC2 protein expression in MDR colorectal carcinoma cells and sensitize these cells to anticancer drugs including oxaliplatin, vincristine, doxorubicin, 5-fluorouracil and mitomycin C [50].”
Roles of miRNAs in Colorectal Cancer: Therapeutic Implications and Clinical Opportunities
Mehrgou, A., Ebadollahi, S., Seidi, K., Ayoubi‐Joshaghani, M. H., Ahmadieh-Yazdi, A., Zare, P., Jaymand, M., & Jahanban‐Esfahlan, R. (2020) · Advanced Pharmaceutical Bulletin · doi:10.34172/apb.2021.029 · Cited by 43
“Mir-227 induces sensitivity to several chemotherapeutics in vitro and in vivo.(67) Mir-378 constrains cell growth in the transition from phase G1 to S, and decreases cell life and colonization in the HT-29 and HCT-116 cell lines.”
Epigenetic regulation of drug transporter expression in human tissues
Hirota, T., Tanaka, T., Takesue, H., & Ieiri, I. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1230199 · Cited by 31
Non-coding RNAs in drug resistance of head and neck cancers: A review
Dai, F., Dai, L., Zheng, X., Guo, Y., Zhang, Y., Niu, M., Lü, Y., Li, H., Hou, R., Zhang, Y., et al. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110231 · Cited by 29
Weng, W., Feng, J., Qin, H., Ma, Y., & Goel, A. (2015) · Future Oncology · doi:10.2217/fon.15.83 · Cited by 28
Guo, R., Yu, Y., Zhang, Y., Li, Y., Chu, X., Lu, H., & Sun, C. (2020) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00302.2019 · Cited by 28
The implications of ABCC3 in cancer drug resistance: can we use it as a therapeutic target?
Ramírez-Cosmes, A., Reyes-Jiménez, E., Zertuche-Martínez, C., Hernández-Hernández, C., García‐Román, R., Romero-Díaz, R. I., Manuel-Martínez, A. E., Elizarrarás-Rivas, J., & Vásquez-Garzón, V. R. (2021) · American Journal of Cancer Research · Cited by 36
Tetievsky, A., Assayag, M., Ben‐Hamo, R., Efroni, S., Cohen, G., Abbas, A., & Horowitz, M. (2014) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00422.2014 · Cited by 27
“The significant differential upregulation of miRNA 297 (rno-miR-297), associated with cellular toxicity and stress gene regulation (11, 76) in this acclimation phase, further supports that AC2d is a strained phase.”
BackgroundWang, D., Li, J., Sha, H., Chen, X., Yang, S., Shen, H.-Y., Zhong, S., Zhao, J., & Tang, J.-H. (2016) · Gene · doi:10.1016/j.gene.2016.06.013 · Cited by 25
Molecular mechanisms and clinical implications of miRNAs in drug resistance of colorectal cancer
Duan, L., Yang, W., Feng, W., Cao, L., Wang, X., Niu, L., Li, Y., Zhou, W. J., Zhang, Y., Liu, J., et al. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920947342 · Cited by 25
Self-citationYao, Y., Jia, H., Wang, G., Ma, Y., Sun, W., & Li, P. (2019) · Cellular Physiology and Biochemistry · doi:10.33594/000000049 · Cited by 23
miRNA‐765 mediates multidrug resistance via targeting BATF2 in gastric cancer cells
Lin, W., Miao, Y., Meng, X., Huang, Y., Zhao, W., & Ruan, J. (2020) · FEBS Open Bio · doi:10.1002/2211-5463.12838 · Cited by 25
Wang, Y., Tu, M.-J., & Yu, A.-M. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1423416 · Cited by 21
Chen, Y., & Chang, L. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.06.009 · Cited by 21
MicroRNA-765 sensitizes osteosarcoma cells to cisplatin via downregulating APE1 expression
Wei, L., Li, C., Li, M., Wang, D., & Zhong, Z. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s194800 · Cited by 20
MicroRNA-134 reverses multidrug resistance in human lung adenocarcinoma cells by targeting FOXM1
Li, J., Chen, Y., Jin, M., Wang, J., Li, S., Chen, Z., & Yu, W. (2017) · Oncology Letters · doi:10.3892/ol.2017.5574 · Cited by 19
“Evidence has emerged for the role of miRNAs in modulating the drug sensitivity and resistance of cells, and numerous studies have demonstrated that the elevation or inhibition of miRNA expression may modulate MDR in cancer cells (7-10).”
An Isoxazole Derivative SHU00238 Suppresses Colorectal Cancer Growth through miRNAs Regulation
Wang, H., Ma, Y., Lin, Y., Liu, J., Chen, R., Xu, B., & Liang, Y. (2019) · Molecules · doi:10.3390/molecules24122335 · Cited by 16
Self-citationMiR-297 inhibits tumour progression of liver cancer by targeting PTBP3
Lu, N., Min, J., Peng, L., Huang, S., Chai, X., Wang, S., & Wang, J. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06097-0 · Cited by 16
Kaur, E., Agrawal, R., Arun, R., Madhavan, V., Srivastava, V., Kumar, D., Rath, P. P., Kumar, N., Sreekanth, V., Pandey, N., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci161941 · Cited by 14
“At present, MRP2 is only known to be downregulated posttranscriptionally by miR-297 (22).”
MiRNAs: main players of cancer drug resistance target ABC transporters
Mohammadi, F., Nejatollahi, M., Sheikhnia, F., Ebrahimi, Y., Mohammadi, M., Rashidi, V., Alizadeh‐Fanalou, S., Azizzadeh, B., & Majidinia, M. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03719-y · Cited by 15
Interactions between anticancer active platinum complexes and non-coding RNAs/microRNAs
Biersack, B. (2016) · Non-coding RNA Research · doi:10.1016/j.ncrna.2016.10.001 · Cited by 13
“Oxaliplatin-resistant CRC cells were sensitized to oxaliplatin treatment by increased miR-297 levels, which reduced the levels of the platinum-resistance associated MRP2 (MDR-associated protein 2) protein in the CRC cells [270].”
MicroRNAs Involved in Oxidative Stress Processes Regulating Physiological and Pathological Responses
Xu, Y., Huang, X., Luo, Q., & Zhang, X. (2021) · MicroRNA · doi:10.2174/2211536610666210716153929 · Cited by 16
Molecular pathways involved in microRNA-mediated regulation of multidrug resistance
Liao, R., Lin, Y., & Zhu, L. (2018) · Molecular Biology Reports · doi:10.1007/s11033-018-4358-6 · Cited by 12
Retinoic Acid Downregulates HSPB8 Gene Expression in Human Breast Cancer Cells MCF-7
Piccolella, M., Cristofani, R., Tedesco, B., Chierichetti, M., Ferrari, V., Casarotto, E., Cozzi, M., Crippa, V., Rusmini, P., Galbiati, M., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.652085 · Cited by 11
“So far, miR-297 has never been reported in any BC study, even if it was identified as tumor suppressor in prostate cancer (35), in colorectal cancer (36) and glioblastoma (37), while in pulmonary adenocarcinoma it has an oncogenic effect (38).”
BackgroundRegulation of drug transporters by microRNA and implications in disease treatment
Chae, Y., Chang, J., Lee, M.-K., Lim, J., Shin, K., & Lee, K. (2021) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-021-00538-8 · Cited by 11
Chemotherapeutic Risk lncRNA-PVT1 SNP Sensitizes Metastatic Colorectal Cancer to FOLFOX Regimen
Wu, S., Yang, X., Tang, W., Familiari, G., Relucenti, M., Aschner, M., Li, X., & Chen, R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.808889 · Cited by 12
“org 10 through regulated MRP-2 expression (38).”
Up‐regulation of miR‐let7a‐5p Leads to Decreased Expression of ABCC2 in Obstructive Cholestasis
Balasubramaniyan, N., Devereaux, M. W., Orlicky, D. J., Sokol, R. J., & Suchy, F. J. (2019) · Hepatology Communications · doi:10.1002/hep4.1433 · Cited by 10
“Over 329 target genes of let7a-5p have been identified in low-throughput or high-throughput miRNA targeting studies from the MiRTarBase miRNA Targets data set, but did not include ABCC2.”
BackgroundInfluentialYuan, J., Zhang, Q. H., Wu, S., Yan, S., Zhao, R., Sun, Y., Tian, X., & Zhou, K. (2021) · Experimental Hematology · doi:10.1016/j.exphem.2021.08.010 · Cited by 9
MicroRNAs and cancer drug resistance: over two thousand characters in search of a role
Gomes, B. C., Rueff, J., & Rodrigues, A. S. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.55 · Cited by 7
“Xu et al.([92]) reported the validation of ABCC2 as a target of miR-297 and consequently the downregulation of its expression.”
BackgroundPrognostic gene expression profile of colorectal cancer
Saadh, M. J., Allela, O. Q. B., Kareem, R. A., Baldaniya, L., Ballal, S., Vashishth, R., Parmar, M., Sameer, H. N., Hamad, A. K., Athab, Z. H., et al. (2025) · Gene · doi:10.1016/j.gene.2025.149433 · Cited by 6
Leal, K., Saavedra, K., Rebolledo, C., & Salazar, L. A. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.704175 · Cited by 6
“The case of hsa-miR-297 has been associated with prostate cancer (52) and with colorectal carcinoma, specifically with drug resistance (53).”
BackgroundEight Differential miRNAs in DN Identified by Microarray Analysis as Novel Biomarkers
Tu, C., Wei, L., Wang, L., & Tang, Y. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s355783 · Cited by 5
[Advances in tumor chemo-resistance regulated by MicroRNA].
Lin, G., & Xu, K. (2014) · PubMed Central · doi:10.3779/j.issn.1009-3419.2014.10.06 · Cited by 4
Self-citationTu, M., & Yu, A. (2023) · Current Drug Metabolism · doi:10.2174/1389200224666230425232433 · Cited by 4
MicroRNAs in Cancer Drug Resistance and Drug Sensitivity
Seca, H., Lima, R. T., & Vasconcelos, M. H. (2014) · Springer eBooks · doi:10.1007/978-3-319-03725-7_11 · Cited by 5
“MiR-222 over-expression decreased ADAM-17 expression, thus decreasing EGFR activation and TGF-α shedding, which in turn reduces P-gp and MRP1 effl ux pump expression (Xu et al. 2012b ).”
BackgroundInfluentialPredicting Human miRNA-like Sequences within Human Papillomavirus Genomes
Gutiérrez, D. A., Varela-Ramírez, A., Rodríguez-Esquivel, M., Mendoza-Rodríguez, M., Ayala-Sumuano, J. T., Pineda, D., Garrido‐Guerrero, E., Jiménez-Vega, F., Aguilar, S., Quiñones, M., et al. (2018) · Archives of Medical Research · doi:10.1016/j.arcmed.2018.10.008 · Cited by 4
“Interestingly, it has been documented that miRNA-297 down-regulates the multidrug resistance protein 2 (MRP-2) expression, sensitizing colorectal carcinoma cells to anti-cancer drugs (62), and also, probably acting as a tumor suppressor decreasing the survival of glioblastoma cells (63).”
BackgroundRole of MicroRNAs in Cancer Drug Resistance
Babu, K. N., & Kilari, S. (2022) · Springer eBooks · doi:10.1007/978-981-16-9186-7_8 · Cited by 2
Overcoming cancer multidrug resistance through inhibition of microparticles
Vysotski, S., Winzelberg, R., & Babayeva, M. (2016) · GSTF Journal of Advances in Medical Research · doi:10.7603/s40782-014-0023-8 · Cited by 4
“In addition, miR-297 was also recently found to play a role in development of MDR by modulating MRP expression in colorectal tumors [51].”
BackgroundLiver and gastrointestinal cancers
Marín, J. J. G., Macías, R. I. R., Herráez, E., Lozano, E., Romero, M. R., Giacomo, S. D., Efferth, T., & Briz, Ó. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816434-1.00007-3 · Cited by 2
Shah, S. P. (2016) · San José State University ScholarWorks (San Jose State University) · doi:10.31979/etd.32pr-8xtr · Cited by 2
“In humans, expression of miR297 in colorectal cancer is negatively related with the expression of a multi-drug resistant gene MRP-2 (Xu et al., 2012).”
BackgroundLeva, G. D., & Garofalo, M. (2014) · Springer eBooks · doi:10.1007/978-3-319-03725-7_5 · Cited by 1
HMG2D: A tool to identify miRNAs/drugs/genes associated with diseases like cancers
Banerjee, A. K., Bhattacharya, R., & Mal, C. (2020) · Meta Gene · doi:10.1016/j.mgene.2020.100699 · Cited by 1
Molecular Analysis of the Involvements of lncRNA in Cancer Development
Bagchi, A. (2021) · Springer eBooks · doi:10.1007/978-981-15-4501-6_153-1 · Cited by 1
Cancer Stem Cells in Therapy Resistance of Colorectal Cancer
Yang, Y., Meng, W., & Wang, Z. (2021) · Handbook of Oxidative Stress in Cancer: Therapeutic Aspects · doi:10.1007/978-981-16-1247-3_102-1 · Cited by 1
Transcriptional and post-transcriptional regulation in testicular toxicity
Adegoke, O. O. (2015) · Figshare · Cited by 1
MicroRNA involvement in breast cancer susceptibility and progression
Gomes, B. C. (2016) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · Cited by 2
Zhang, P. (2018) · Journal of Medical & Surgical Pathology · doi:10.4172/2472-4971.1000173
Molecular Analysis of the Involvements of lncRNA in Cancer Development
Bagchi, A. (2022) · Springer eBooks · doi:10.1007/978-981-15-9411-3_153
Cancer Stem Cells in Therapy Resistance of Colorectal Cancer
Yang, Y., Meng, W., & Wang, Z. (2022) · Handbook of Oxidative Stress in Cancer: Therapeutic Aspects · doi:10.1007/978-981-16-5422-0_102
Women in Cardiovascular Genetics and Systems Medicine
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-4796-0
MicroRNAs in colorectal cancer drug resistance
Basera, A., Fadebi, O. O., Manabile, M. A., Reis, R. M., & Dlamini, Z. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-33475-7.00006-8
Epigenetic-related drug resistance
Loren, P., & Salazar, L. A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-18722-3.00043-8
Metadata
- Authors
- Xu, K., Liang, X., Shen, K., Cui, D., Zheng, Y., Xu, J., Fan, Z., Qiu, Y., Li, Q., Ni, L., & Liu, J.
- Affiliations
- East China University of Science and Technology (CN)
- Shanghai University of Traditional Chinese Medicine (CN)
- Shanghai Jiao Tong University (CN)
- Corresponding author
- Xu, Ke
- Liang, Xin
- Shen, Ke
- Cui, Daling
- Zheng, Yuanhong
- Liu, Jianwen
- Venue
- Biochemical Journal
- Publisher
- Portland Press Ltd.
- Published
- 2012-08-14
- Volume
- 446
- Issue
- 2
- Pages
- 291-300
- ISSN
- 0264-6021 (ISSN-L)
- 1470-8728
- OpenAlex
- W2001233915
- Cited by
- 93
- References
- 51
- Citations by year
- 2025: 4 · 2024: 4 · 2023: 2 · 2022: 6 · 2021: 9 · 2020: 7 · 2019: 7 · 2018: 6 · 2017: 7 · 2016: 15 · 2015: 7 · 2014: 10 · 2013: 7 · 2012: 2
- FWCI
- 4.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Biochemical Journal (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Keywords
- microRNA, multidrug resistance, colorectal cancer, MRP2, TAP1, platinum resistance, chemosensitization, miRNA expression profiling, efflux pumps
- MeSH terms
- Multidrug Resistance-Associated Protein 2, Adenocarcinoma, Aged, Antineoplastic Agents, Female, Humans, Male, Middle Aged, Neoplasm Proteins, RNA, Messenger, RNA, Neoplasm, Colorectal Neoplasms, Genetic Therapy, Down-Regulation, Drug Resistance, Multiple, Drug Resistance, Neoplasm, Gene Silencing, ATP-Binding Cassette, Sub-Family C Proteins, Multidrug Resistance-Associated Proteins, RNA, Small Interfering, MicroRNAs, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.